Sanofi Reports observational study Data for Cilofexor in Hepatitis C

Sanofi today announced observational study results for Cilofexor in patients with Hepatitis C. The study demonstrated that Cilofexor demonstrates sustained long-term efficacy compared to standard of care or placebo. These results provide important insights into the treatment of Hepatitis C and support the continued development of Cilofexor in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Cilofexor was consistent with previous observations, with no new safety signals identified.